Table 3.
Logistic regression for VAS pain score of ≤10 and ≤20 mm at week 24: multivariable analysis with pairwise comparison
| Baseline parameter | Pairwise comparison | VAS pain score ≤10 mm | VAS pain score ≤20 mm | ||
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| Age, years | 1 unit increase | – | – | 0.99 (0.99 to 1.00) | 0.016 |
| Anti-CCP or RF positive | Yes vs no | 1.46 (1.14 to 1.88) | 0.003 | 1.35 (1.09 to 1.67) | 0.007 |
| BMI, kg/m2 | 1 unit increase | 0.98 (0.96 to 0.99) | 0.009 | 0.98 (0.96 to 0.99) | 0.002 |
| CDAI | 1 unit increase | 1.03 (0.97 to 1.10) | 0.283 | 1.04 (0.99 to 1.10) | 0.145 |
| Concurrent oral corticosteroids | Yes vs no | 0.79 (0.66 to 0.95) | 0.014 | 0.78 (0.66 to 0.92) | 0.003 |
| DAS28-CRP | 1 unit increase | 1.54 (1.06 to 2.24) | 0.024 | 1.69 (1.20 to 2.37) | 0.002 |
| Duration of RA, years | 1 unit increase | 0.98 (0.97 to 0.99) | 0.007 | 0.99 (0.98 to 1.00) | 0.100 |
| Ethnicity | Hispanic/Latino vs not Hispanic/Latino | 1.04 (0.68 to 1.59) | 0.851 | 0.79 (0.54 to 1.16) | 0.233 |
| FACIT-Fatigue | 1 unit increase | 0.99 (0.98 to 1.01) | 0.497 | 1.00 (0.99 to 1.01) | 0.914 |
| HAQ-DI | 1 unit increase | 0.95 (0.75 to 1.19) | 0.629 | 1.07 (0.87 to 1.31) | 0.528 |
| Pain VAS score, mm | 1 unit increase | 1.00 (0.99 to 1.00) | 0.340 | 1.00 (0.99 to 1.01) | 0.511 |
| Patient global VAS score, mm | 1 unit increase | 0.99 (0.98 to 1.00) | 0.170 | 0.99 (0.98 to 1.00) | 0.014 |
| Physician global VAS score, mm | 1 unit increase | – | – | 1.00 (0.99 to 1.00) | 0.635 |
| Race | Asian vs White | 0.95 (0.55 to 1.64) | 0.865 | 1.15 (0.57 to 2.34) | 0.701 |
| Black/African American vs White | 0.95 (0.55 to 1.64) | 0.848 | 0.67 (0.40 to 1.11) | 0.117 | |
| Other vs White | 1.13 (0.75 to 1.70) | 0.548 | 0.99 (0.67 to 1.46) | 0.970 | |
| Region | Asia+Southeast Asia vs North America | 0.70 (0.30 to 1.59) | 0.390 | 0.69 (0.33 to 1.47) | 0.337 |
| Eastern Europe vs North America | 0.84 (0.61 to 1.16) | 0.287 | 0.92 (0.69 to 1.23) | 0.569 | |
| South/Central America vs North America | 1.62 (1.00 to 2.61) | 0.050 | 1.88 (1.21 to 2.94) | 0.005 | |
| Western Europe+Other vs North America | 0.99 (0.69 to 1.42) | 0.971 | 0.86 (0.62 to 1.20) | 0.385 | |
| SDAI | 1 unit increase | 0.97 (0.91 to 1.04) | 0.381 | 0.95 (0.89 to 1.01) | 0.078 |
| SF-36 MCS | 1 unit increase | 1.03 (1.02 to 1.04) | <0.001 | 1.03 (1.01 to 1.04) | <0.001 |
| SF-36 PCS | 1 unit increase | 1.05 (1.03 to 1.07) | <0.001 | 1.04 (1.03 to 1.06) | <0.001 |
| Sex | Female vs male | 0.90 (0.72 to 1.14) | 0.383 | – | – |
| Smoking status | Current vs never | 1.22 (0.93 to 1.59) | 0.148 | 1.15 (0.91 to 1.46) | 0.237 |
| Former vs never | 1.72 (1.32 to 2.24) | <0.001 | 1.63 (1.28 to 2.08) | <0.001 | |
| TJC28 | 1 unit increase | 0.93 (0.89 to 0.96) | <0.001 | 0.95 (0.91 to 0.98) | 0.002 |
| Treatment | Adalimumab vs placebo | 1.90 (1.30 to 2.79) | <0.001 | 1.81 (1.33 to 2.48) | <0.001 |
| FIL100 vs placebo | 2.38 (1.74 to 3.24) | <0.001 | 2.04 (1.59 to 2.62) | <0.001 | |
| FIL200 vs placebo | 3.18 (2.34 to 4.32) | <0.001 | 2.78 (2.16 to 3.56) | <0.001 | |
The model included treatment group, study, baseline VAS pain score and all of the additional predictors shown.
Anti-CCP, anti-cyclic citrullinated peptide; BMI, Body Mass Index; CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score-28 with C-reactive protein; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy–Fatigue; HAQ-DI, Health Assessment Questionnaire–Disability Index; MCS, Mental Component Summary score; PCS, Physical Component Summary score; RF, rheumatoid factor; SDAI, Simple Disease Activity Index; SF-36, 36-item short-form health survey; TJC28, tender joint count based on 28 joints; VAS, visual analogue scale.